Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Revance Therapeutics (RVNC) Gets a Hold From Mizuho Securities
Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)
Guggenheim Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.66
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Revance Therapeutics Analyst Ratings
Barclays Downgrades Revance Therapeutics to Equalweight From Overweight, Price Target Is $7
Barclays Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $7
H.C. Wainwright Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.6
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Maintaining Hold on Revance Therapeutics Amid Merger Developments and Positive Sales Forecast
A Quick Look at Today's Ratings for Revance Therapeutics(RVNC.US), With a Forecast Between $6.6 to $12
Revance Therapeutics Analyst Ratings
Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $6
Revance Therapeutics Price Target Maintained With a $12.00/Share by Needham
Revance Therapeutics Analyst Ratings
Buy Rating Affirmed on Revance Therapeutics Amid Strong Product Performance and Strategic Market Expansion
HC Wainwright & Co. : Revance Therapeutics (RVNC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Revance Therapeutics Analyst Ratings
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)